Johnson & Johnson's $1.61B Trading Volume Surge to 38th in Market Activity Driven by Groundbreaking PFA Advances and 0.5% Gains

On September 2, Johnson & Johnson (JNJ) recorded a trading volume of $1.61 billion, a 30.98% increase from the previous day, ranking 38th in market activity. The stock closed with a 0.50% gain, reflecting renewed investor interest in the healthcare giant's recent developments in cardiac ablation technology.

Johnson & Johnson MedTech announced compelling results from the VARIPURE substudy of SECURE, evaluating its VARIPULSE™ Platform for pulsed field ablation (PFA) in atrial fibrillation (AF). The real-world data from 791 patients across 20 European centers showed a 0.6% primary adverse event rate with no strokes, alongside 99.7% acute pulmonary vein isolation (PVI) and high procedural efficiency. The platform’s integration with the CARTO™ 3 System was highlighted for enabling consistent, reproducible workflows, reinforcing its potential to reshape AF treatment standards.

Additional evidence from the REAL AF Registry, spanning 70 U.S. and Canadian sites, further validated the platform’s safety. Among 200 cases, 80% utilized a 30mL irrigation flow rate, with no strokes, deaths, or device-related hospitalizations reported. Jennifer Currin, VP of Scientific Affairs at J&J MedTech, emphasized the company’s commitment to generating robust clinical data to support widespread adoption of PFA technology.

The VARIPURE study’s methodological rigor, including prospective data collection and meticulous monitoring, positions it as a benchmark for PFA research. With regulatory approvals in the U.S., Europe, and Asia-Pacific, the VARIPULSE™ Platform’s expanding real-world evidence base strengthens its role in advancing patient-centered care for heart rhythm disorders.

The backtest results demonstrated a 0.6% adverse event rate and 99.7% acute PVI across nearly 800 patients, confirming the platform’s consistent performance in diverse clinical settings.